EN | SE Contact us

Meet us

Nov 2-6, 2020, Festival of Biologics, Basel, Switzerland

Nov 9-13, 2020, PEGS Europe, Lisbon, Portugal

Nov 9-14, 2020, SITC

Other news

Healthcare Direkt - Interview with Martin Welschof, CEO, October 28, 2020 > Interview

Di – License agreement BI-1206 for China, October 27, 2020 > Link

Di tv - Interview with Martin Welschof, CEO, October 27, 2020 > Interview

Pareto-TV - Interview with Martin Welschof, CEO, October 27, 2020 > Interview

Interview with Dharminder Chahal, Board member of BioInvent, September 23, 2020 > Interview

Key Opinion Leader call – July 21, 2020 > Replay

BioInvent develops antibodies for the treatment of cancer

BioInvent is generating value for shareholders by employing its antibody and cancer biology expertise to identify antibodies with novel mechanisms-of-action and novel oncology targets. The Company employs this approach to generate therapeutic immuno-modulating antibodies that can be developed for a broad range of cancer indications. The Company plans to bring these antibodies to the clinic through its own resources and together with partners.

1907 FP Imonc

Immuno-oncology - a revolution in cancer treatment

The body’s immune defense is one of the most effective weapons to fight cancer. Development of new immuno-oncology drugs directing the immune defense against the tumour is expected to revolutionize the treatment.



Mission and strategy

BioInvent’s primary goal is to develop next generation immuno-oncological drugs with a focus on improving therapeutic results in areas with significant unmet need.



Business model

BioInvent has three main areas for commercialization. The Company's primary value drivers are clinical and preclinical development projects.


1907 FP Howtoreach

How to reach us

Located within the Ideon Science Park, Sweden, we are easy to access by road and air.

Contact us





Two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively.


A collaboration with Pfizer Inc. for the development and commercialization of new antibody therapies directed towards tumor associated myeloid cells.

BI-1808 and BI-1910

BioInvent has identified TNFR2, a member of the so called TNFR superfamily as a target within the Treg program.


BioInvent and Transgene collaborate to co-develop oncolytic virus candidates encoding a validated anti-CTLA-4 antibody sequence.


BioInvent is currently developing antibodies specific for currently undetermined Treg targets and functions as well as for known targets.

Our tools for successful drug development



In an automated process, we select new drug candidates from our own antibody library – one of the largest in the world.


Our unique and patented development tool has the advantage of simultaneously identifying disease-associated targets and antibodies that bind to them.


Our cGMP certified manufacturing site provides antibodies for in-house project development, as well as for external customers.


  • +/-
  • +/-
  • Opening price
  • Bid
  • Ask
  • High
  • Low
  • Volume
  • Turnover
  • Updated